Bristol-Myers Squibb and Gilead Sciences have formed an agreement to commercialize Atripla in Europe for the treatment of virologically suppressed adults with HIV-1 infection. If approved in the EU, Atripla would represent that region’s the first and only once-daily single tablet regimen for HIV-1 infection. The companies expect the European Commission to issue its decision by the end of the year. BMS and Gilead have agreed to share responsibility for commercializing the drug throughout...